Ischemic Heart Disease
📧 Sign up to get email alerts when something new happens for Ischemic Heart Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-02-16FDA Approved: NITROGLYCERIN — Original Application (Cosette Pharmaceuticals, Inc.)
FDA approves Cosette Pharmaceuticals' generic nitroglycerin under an original ANDA.
-
FDA approval · 2023-12-27FDA Approved: METOPROLOL SUCCINATE — Supplemental Application (Nivagen Pharmaceuticals, Inc.)
FDA approved a supplemental application for metoprolol succinate (Toprol-XL) under an ANDA from Nivagen Pharmaceuticals.
-
FDA approval · 2023-12-22FDA Approved: TENORMIN — Supplemental Application (Almatica Pharma LLC)
FDA approves a supplemental application for Tenormin (atenolol) filed by Almatica Pharma LLC.
-
FDA approval · 2023-12-05FDA Approved: NITROGLYCERIN — Original Application (Lifestar Pharma LLC)
FDA approved an original application for nitroglycerin from Lifestar Pharma LLC, enabling a generic nitroglycerin product.
-
CLINICAL_TRIALS trial_result · 2023-11-21Clinical Trial Update: 68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease [Phase 2]
Phase 2 clinical trial evaluating a 68Ga-NODAGA-E[c(RGDγK)]2 PET tracer for imaging angiogenesis in chronic ischemic heart disease.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: A Clinical Evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions
A completed clinical trial evaluating the MINI TREK RX 1.20 mm coronary dilatation catheter in stenotic coronary lesions with results posted…
-
FDA approval · 2023-10-26FDA Approved: NITROGLYCERIN — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for nitroglycerin by Aurobindo Pharma Limited, a generic version of the drug.
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: Cardio-protective Effect of Metformin in Patients Undergoing PCI [Phase 3]
Phase 3 trial investigating whether metformin provides cardio-protective effects in patients undergoing percutaneous coronary intervention.
-
FDA approval · 2023-09-12FDA Approved: METOPROLOL SUCCINATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for metoprolol succinate from Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2023-08-30Clinical Trial Update: Preventive VT Substrate Ablation in Ischemic Heart Disease [Phase 3]
Phase 3 clinical trial update on preventive substrate ablation for ventricular tachycardia in ischemic heart disease (status: unknown).
-
FDA approval · 2023-08-09FDA Approved: ZOCOR — Supplemental Application (Organon LLC)
FDA approved a Supplemental Application for ZOCOR (simvastatin) submitted by Organon LLC.
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes [Phase 2]
Phase 2 study evaluating flurpiridaz (18F) injection for PET imaging to assess myocardial perfusion quality, completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-07-17Clinical Trial Update: A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk [NA]
A completed clinical trial evaluated a smartphone-based application to manage cardiovascular disease risk after myocardial infarction in pat…
-
FDA approval · 2023-06-06FDA Approved: NITROGLYCERIN — Supplemental Application (Dr. Reddys Laboratories Inc)
FDA approved a supplemental application for nitroglycerin submitted by Dr. Reddys Laboratories Inc.
-
FDA approval · 2023-06-05FDA Approved: DEFINITY — Supplemental Application (Lantheus Medical Imaging, Inc.)
FDA approved a supplemental application for DEFINITY (perflutren) submitted by Lantheus Medical Imaging, Inc.
-
CLINICAL_TRIALS trial_result · 2023-06-02Clinical Trial Update: XTR003 PET Radiotracer for the Detection of Viable Myocardium [Phase 2]
Phase 2 clinical trial update for XTR003 PET radiotracer aiming to detect viable myocardium in ischemic heart disease.
-
FDA approval · 2023-05-25FDA Approved: EPTIFIBATIDE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for the generic drug Eptifibatide filed by Eugia US LLC (ANDA 206127).
-
FDA approval · 2023-05-12FDA Approved: AMMONIA N 13 — Supplemental Application (SOFIE Co. dba SOFIE)
FDA approved a supplemental application for Ammonia N-13 (AMMONIA N-13) from SOFIE Co. dba SOFIE, updating its regulatory approval. This app…
-
FDA approval · 2023-04-25FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for atorvastatin calcium by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2023-04-12FDA Approved: PRASUGREL — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for the generic prasugrel from Accord Healthcare Inc., finalizing a regulatory action under the ANDA…
-
CLINICAL_TRIALS trial_result · 2023-04-04Clinical Trial Update: The Randomized OPTIMAL-ACT Trial [Phase 2]
A Phase 2 randomized trial (OPTIMAL-ACT) completed with results posted in 2023, evaluating treatment in coronary artery disease and ischemic…
-
FDA approval · 2023-02-23FDA Approved: EPTIFIBATIDE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for the generic Eptifibatide from Mylan Institutional LLC. The approval updates the product's regula…
-
FDA approval · 2023-02-02FDA Approved: REGADENOSON — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approves Hikma Pharmaceuticals USA Inc. for Regadenoson (ANDA 215827) as a generic injectable pharmacologic stress agent for myocardial …
-
CLINICAL_TRIALS trial_result · 2023-01-13Clinical Trial Update: Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
A completed clinical trial assessing myocardial ischemic-reperfusion injury in off- and on-pump CABG procedures; results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Regadenoson Real Time Perfusion Imaging Trial-Optison [Phase 3]
Phase 3 trial evaluating regadenoson real-time perfusion imaging with Optison has completed and results posted.